US 2022/0016239 A1 · METHOD FOR TREATING CANCER USING ARTIFICIAL ADJUVANT CELL (aAVC)

Abstract

[Problem to be Solved] Provided is an effective and safe method for treating or preventing a cancer using aAVC. [Solution] The present invention finds suitable ranges of the dose of α-GalCer loaded on aAVC cell surface, and the amount of α-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.

Claims6

Dependent claims

A method for treating or preventing a cancer, comprising the step of administering a human-derived cell to a human,

wherein the cell expresses exogenous CD1d, has α-galactosylceramide (α-GalCer) loaded on the cell surface,
and wherein the cell is administered to the human such that a single dose of α-GalCer loaded on the cell surface ranges from 1.7 ng to 275 ng per kg body weight of the human.

Dependencies are inferred from the claim text.

Facts

Application

17/312,363Filed 1 Dec 2020

Priority

JP 2019-2177122 Dec 2019

Published

20 Jan 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 35/22
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically…:…
A61K 39/001153
Transcription factors, e.g. SOX or c-MYC: wilms tumor 1 [WT1]
A61P 35/00
Antineoplastic agents

METHOD FOR TREATING CANCER USING ARTIFICIAL ADJUVANT CELL (aAVC)

Life of this patent

METHOD FOR TREATING CANCER USING ARTIFICIAL ADJUVANT CELL (aAVC)

Life of this patent

Abstract

Claims6